-
Electronic (PDF)
-
Site License
-
Enterprisewide
Psychosis - Pipeline Review, H2 2011
Global Markets Direct, October 2011, Pages: 42
Psychosis - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Psychosis - Pipeline Review, H2 2011', provides an overview of the Psychosis therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. 'Psychosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Psychosis.
- A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psychosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Psychosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Psychosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Psychosis Overview
Therapeutics Development
An Overview of Pipeline Products for Psychosis
Psychosis Therapeutics under Development by Companies
Psychosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Psychosis Therapeutics - Products under Development by Companies
Psychosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Psychosis Therapeutics Development
H Lundbeck A/S
ACADIA Pharmaceuticals Inc.
Aton Pharma, Inc.
Psychosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Zicronapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-831 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pimavanserin Tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ceftriaxone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valtrex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ziprasidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THC + Iomazenil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATON 005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Psychosis Therapeutics – Drug Profile Updates
Psychosis Therapeutics - Discontinued Products
Psychosis - Featured News
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
